ABSTRACT Nine patients with severe chronic airway obstruction secondary to chronic bronchitis and emphysema all preferred nebulised salbutamol solution to placebo in a double-blind controlled trial. Four of the patients who had previously received domiciliary nebulised salbutamol failed to complete the placebo period, though all completed the active period. Five others improved subjectively on active therapy, and showed a significant improvement in morning and evening peak flows. Symptom scores for breathlessness, wheezing, and sputum production were lower in the active treatment period and standard aerosol usage fell, although these changes might have been due to chance. Patients with severe chronic airway obstruction who do not respond to conventional bronchodilator therapy should be considered for this form of treatment.
Chronic bronchitis and emphysema affect about one million people in the United Kingdom. The major aetiological factor in both conditions is cigarette smoking, although it is not known why one smoker develops predominant chronic bronchitis while another develops predominant emphysema. In widespread severe emphysema the respiratory drive is well maintained, the oxygen saturation is near normal at rest, and the patient becomes a typical "pink puffer". He suffers from unrelenting breathlessness-often so severe that he has difficulty in eating, washing, or dressing. The treatment of this condition is disappointing for both patient and doctor. There is little or no response to corticosteroids, or to oral and inhaled bronchodilators.
Recently, in an uncontrolled trial, patients claimed considerable relief from regular nebulised salbutamol solution given at home.' We decided to extend this study to a double-blind controlled trial using an inert placebo solution versus salbutamol solution in the patient's home.
Methods
In the study, double-blind and cross-over in design, each patient was studied for four weeks, two weeks on inert placebo solution via a nebuliser (2 ml four times daily) and two weeks on a mixture of 1 ml (5 mg) salbutamol respirator solution plus 1 ml of sterile water (2 ml four times daily). The nebuliser was driven by an electric air compressor. The order of each medication period was predetermined by random selection. Both solutions were identical in appearance and were packed in identical containers. Each patient was also given a standard active salbutamol aerosol inhaler for intermittent emergency use only and the number of times this was used was recorded daily.
Nine male and one female patient, age range 47-81 years, were studied. All had severe chronic airway obstruction with marked dyspnoea. They had all been given a high dose corticosteroid trial with little or no subjective or objective benefit. Nine patients were ex-smokers, and one continued to smoke "three cigarettes daily".
Eight patients had chronic bronchitis.2 Nine patients showed radiological evidence of emphysema with low flat diaphragms, a large retrosternal airspace, and pruning of the peripheral vessels.3 All had large total lung capacities and reduced transfer factors.
Three patients continued on 5 mg prednisone daily, while seven received no other medication for their airway obstruction other than the emergency aerosol supplied.
Before the study, peak expiratory flow (PEF) was measured on a Wright's peak flow meter, forced expiratory volume in one second (FEV,) and vital capacity (VC) were measured on a dry bellows spirometer. Total lung capacity was R S E Wilson and S J Connellan measured by the helium dilution method, and carbon monoxide transfer factor by the single breath technique. 4 .
In six patients a 12-minute walk test was carried out on a treadmill. This was performed after 200 ,tg of salbutamol was given by aerosol, and again after 5 mg of nebulised salbutamol solution. The treadmill was set at a comfortable walking speed for each individual (usually 2 kph) without any incline. The patients were asked to walk until they reached the point at which they would usually stop for a breather. It was stressed that they should not push themselves past this mark. Distances walked and the number of stops were noted over a period of 12 minutes. The patient's electrocardiogram and heart rate were monitored throughout.
Each patient was supplied with a daily diary booklet and the following observations were noted for day (0700-1900) and night (1900-0700): severity of wheeze, cough, sputum, sleeplessness, sideeffects, and the number of times the emergency salbutamol aerosol inhaler was used. Peak expiratory flow rate was recorded morning and evening -three attempts were made at each time of day 30 minutes after nebuliser therapy and the best reading in the morning and evening has been assessed.
Any patient unable to complete the first period of the trial informed an investigator who, having broken the code, decided whether the patient should continue on the second period.
Results
Of the 10 patients in the study, one was withdrawn because of mechanical failure in the air compressor. Four other patients withdrew during the placebo period because of an increase in symptoms (two during the first two weeks and two during the second). Those who withdrew in the first two weeks were then asked to change to the second two weeks of treatment, and were able to complete this period. These four patients had received regular nebulised salbutamol at home for several months before the trial.
Five patients, none of whom had previously received nebulised salbutamol, completed the trial and these were further assessed.
Physiological data are shown in In the present study, four patients who had received nebulised salbutamol at home before the study found that symptoms were intolerable during the placebo period and dropped out of the trial, although when this occurred during the first treatment period they were able to complete the second two weeks when they were unknowingly receiving active therapy.
The five patients who completed the trial all preferred the active treatment period. Three volunteered that they were better symptomatically than they had been for some years, and were anxious to continue on nebulised salbutamol.
One other patient felt sufficient improvement to continue, but the remaining patient felt that the improvement was not enough to change from his usual treatment of regular salbutamol pressurised aerosol. Night  5  27  26  22  22  27  30  24  25  16  0  13  0  56  0  48  0   7   31  33  33  32  36  34  30  26  14  15  5  3  20  9  17  8  8   17  16  14  14  28  28  28  28  14  14  14  14  0  0  0  0  9  38  13  29  15  14  12  9  2  7  0  2  0  85  2  78  7  10  38  42  21  35  31  35  14  21  17  17  15  14  36 
